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Background: Carbonic anhydrase enzymes (CA) catalyze the reversible hydration of carbon dioxide to bicarbonate
in mammalian cells. Trans-membrane transport of CA-produced bicarbonate contributes significantly to cellular pH
regulation. A body of evidence implicates pH-regulatory processes in the hypertrophic growth pathway
characteristic of hearts as they fail. In particular, Na+/H+ exchange (NHE) activation is pro-hypertrophic and CA
activity activates NHE. Recently Cardrase (6-ethoxyzolamide), a CA inhibitor, was found to prevent and revert
agonist-stimulated cardiac hypertrophy (CH) in cultured cardiomyocytes. Our goal thus was to determine whether
hypertrophied human hearts have altered expression of CA isoforms.
Methods: We measured CA expression in hypertrophied human hearts to begin to examine the role of carbonic
anhydrase in progression of human heart failure. Ventricular biopsies were obtained from patients undergoing
cardiac surgery (CS, n = 14), or heart transplantation (HT, n = 13). CS patients presented mild/moderate concentric
left ventricular hypertrophy and normal right ventricles, with preserved ventricular function; ejection fractions
were ~60%. Conversely, HT patients with failing hearts presented CH or ventricular dilation accompanied by
ventricular dysfunction and EF values of 20%. Non-hypertrophic, non-dilated ventricular samples served as controls.
Results: Expression of atrial and brain natriuretic peptide (ANP and BNP) were markers of CH. Hypertrophic
ventricles presented increased expression of CAII, CAIV, ANP, and BNP, mRNA levels, which increased in failing
hearts, measured by quantitative real-time PCR. CAII, CAIV, and ANP protein expression also increased approximately
two-fold in hypertrophic/dilated ventricles.
Conclusions: These results, combined with in vitro data that CA inhibition prevents and reverts CH, suggest that
increased carbonic anhydrase expression is a prognostic molecular marker of cardiac hypertrophy.
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Heart failure places an increasingly heavy disease burden
on populations world-wide, leading to a need to under-
stand basic mechanisms underlying the disease [1]. Identi-
fication of basic mechanisms that promote the downward
cascade of heart failure holds the promise to develop tar-
geted new therapeutic strategies. Altered ion homeostasis
contributes to hypertrophic heart growth, which impairs
the heart’s ability to pump effectively and commonly pro-
gresses to heart failure. Cardiac Na+/H+ exchanger 1* Correspondence: Joe.casey@ualberta.ca
2Department of Biochemistry, and Membrane Protein Disease Research
Group, University of Alberta, Edmonton, AB T6G 2H7, Canada
Full list of author information is available at the end of the article
© 2013 Alvarez et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(NHE1) is central to maintenance of intracellular pH. In-
deed, experimental and clinical studies demonstrated the
pathophysiological implications of increased NHE1 activ-
ity during an ischemic episode and in hypertrophy [2-4].
NHE1 activity is detrimental to the myocardium as a re-
sult of increased intracellular Na+ load, leading to elevated
intracellular Ca2+ through the action of Na+/Ca2+ exchan-
ger, NCX1. In some studies, increased cardiac expression
of NHE1 protein appears to be involved in the subsequent
pathological changes [5]. In human heart failure, however,
enhanced NHE1 activity is not correlated with increased
NHE1 expression, suggesting a role for activation by post-
translational mechanisms [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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way, such as Cl-/HCO3
- exchange mediated by AE3, since
NHE activity alkalinizes the cell, resulting in self inacti-
vation through a cytosolic modifier site [7,8]. Hyperacti-
vation of NHE1 and AE3 exchanger are associated with
hypertrophic heart growth, in a model of spontaneously
hypertensive rats [9]. Maximal activity of AE3 and
NHE1 require the catalytic activity of the enzyme car-
bonic anhydrase (CA), which provides the HCO3
- and H+
substrate for the two transporters [10-12]. Treatment of
cultured rat cardiomyocytes with the CA inhibitor,
ethoxyzolamide (Cardrase), prevented hormonally-
induced hypertrophy and reversed it once established
[13]. ETZ also normalized spontaneous Ca++ transients
induced by pro-hypertrophic hormones, indicating that
CA has a role in the elevated Ca++ found in the hyper-
trophic heart [13]. The identity of the CA isoform re-
sponsible for the anti-hypertrophic effects was not
established in the earlier work. Together, CA inhibition,
a therapy previously used for diuresis targeting hyper-
tension and heart failure [14], may be an effective thera-
peutic approach towards mitigation of the heart disease.
Beneficial effects of NHE inhibition in the failing heart
have been suggested on the basis of cellular signalling
mechanisms and experimental studies [5,15]. Here we
examined the expression of the CA isoforms, CAII and
CAIV, in normal, hypertrophic and failing human hearts.
Our data lead to the conclusion that increased CA expres-
sion is a marker of hypertrophic heart, which progresses
towards failure, and suggests that CA inhibition is a point
to intervene in the hypertrophic cascade. Limiting sub-
strate availability for NHE1 and AE3 intracellular pH
regulatory mechanisms by inhibition of CA will impair the
signals that trigger the hypertrophic heart growth.
Methods
Human ethics and heart sample collection
The study was approved the Human Research Ethics
Board, Faculty of Medicine and Dentistry, University of
Alberta and all patients gave written informed consent.
To avoid possible disease-specific confounding factors,
only samples from patients with early-stage hypertrophy
(aortic stenosis, valve replacement or coronary artery by-
pass surgery) were used.
End-stage failing hearts (severe cardiomyopathy, heart
transplantation), were biopsied following explantation
associated with cardiac transplant surgery. Samples were
collected from right or left free ventricular wall as indi-
cated. Endomyocardial biopsy samples (EMBs), from
patients who were referred to the University of Alberta
Hospital for evaluation of cardiomyopathy, were col-
lected by needle biopsy (average diameter 3 mm), and
immediately placed into microcentrifuge tubes contain-
ing 4°C RNAlaterW (Qiagen, Canada) for storage.RNA isolation and cDNA synthesis
RNA was isolated from human heart ventricles and
human brain cortex (from Cooperative Human Tissue
Network (http://www.chtn.nci.nih.gov/)), and used as a
control) with RNeasy Micro kit (Qiagen, Canada),
according to the manufacturer’s instructions. Isolated
RNA was treated with DNase I (2 U/ng of RNA; Qiagen)
at 22°C, 15 min. RNA integrity was confirmed by agar-
ose gel electrophoresis.
cDNA synthesis was carried out with Superscript III
reverse transcriptase (Invitrogen, Life Technologies),
according to the manufacturer’s instructions. cDNA
sequences were obtained from the GenBank sequence
database of the National Centre for Biotechnology Infor-
mation (http://www.ncbi.nlm.nih.gov/). Primers were
designed with the Oligo software of the DNA Star pro-
gram (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.
cgi). In conventional RT-PCR, all primers generated only
one amplification band visualized by agarose gel electro-
phoresis. Sequences for all PCR primers are presented in
Additional file 1: Table S1.
Real-time qPCR
Real-time reverse transcription PCR- Real time PCR was
performed with Corbett Rotor-Gene 3000 Real Time ana-
lyser (Corbett Life Science, Australia). Real time PCR reac-
tion contained 25 μL with 12.5 μL of 2X PlatinumW
SYBRW Green qPCR SuperMix-UDG (Invitrogen), 5
pmol/primer and 5 μL of template and cDNA prepared
from 100 ng total RNA. Cycle threshold values (Ct) were
obtained for CAII, CAIV, CAXIV, ANP, BNP, and
GAPDH. GAPDH, assumed not to vary between samples,
was used to normalize for differences in the efficiency of
mRNA isolation from the samples as follows. Ct values
were corrected for each sample by addition or subtraction
of cycles so that GAPDH Ct values were the same.
Protein analysis
Explanted heart samples were rapidly placed in RNAlaterW
and stored at 4°C. Tissue was disrupted in PBS Buffer
(140 mM NaCl, 3 mM KCl, 6.5 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.5), containing protease inhibitors (PI,
MiniComplete Tablet, Roche). After disruption, ventricular
lysates were prepared by addition of SDS-PAGE sample
buffer, heated at 70°C, 3 min, and centrifuged 10 min at
16,110 x g.
Protein expression and tissue culture
Expression constructs of human CAII, rabbit CAIV, and
mouse CAXIV, have been described previously [16-18].
HEK293 cells were individually transfected with empty
vector (pCDNA3), CAII, CAIV, or CAXIV, cDNAs [17].
Cells were grown at 37°C in an air/CO2 (19:1) environ-
ment in DMEM, with 5% (v/v) fetal bovine serum and
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HEK293 cells were washed in PBS buffer and cell lysates
were prepared by addition of 150 μl SDS-PAGE sample
buffer to each 60 mm tissue culture dish. Protein sam-
ples were transferred to PVDF membranes and then
incubated with rabbit anti-human CAII (rabbit poly-
clonal H-70, Santa Cruz, CA; 1:1000 dilution), goat anti-
CAIV antibody (goat polyclonal N-16; Santa Cruz
Biotechnology; 1:500), goat anti-CAXIV antibody (goat
polyclonal N19, Santa Cruz Biotechnology; 1:1000), goat
anti-atrial natriuretic factor antibody (goat polyclonal
N-20; Santa Cruz Biotechnology; 1:200), or rabbit anti-
α-actinin antibody (rabbit polyclonal H-300, Santa Cruz,
CA, USA; 1:500). Immunoblots were then incubated
with donkey anti-rabbit IgG conjugated to horseradish
peroxidase (HRP), mouse anti-goat IgG conjugated to
HRP, or sheep anti-mouse IgG conjugated to HRP (GE
Healthcare, Little Chalfont, UK; 1:2000), as appropriate.
Blots were visualized and quantified using ECL reagent
and a Kodak Image Station.
Isolation and culture of cardiomyocytes
Adult mice were anesthetized with sodium pentobarbital,
150 mg/kg i.p. Animal protocols were approved by the
University of Alberta Animal Policy and Welfare Commit-
tee and performed in accordance with Canadian Council
on Animal Care guidelines. Hearts were excised, and ven-
tricular myocytes obtained by enzymatic dissociation [13].
Statistics
Data are expressed as mean ± SEM. Student Paired
t-test or one-way ANOVA followed by Neuwman-Keuls
Multiple Comparison post-test analysis, when appropri-
ate, were used to compare data. P < 0.05 was considered
of statistical significance.
Results
Patient cohort
Clinical conditions of two patient cohorts are summarized.
Patients undergoing cardiac interventions had good prog-
nosis and good cardiac contractility measured by left
ventricular ejection fraction values of 59 ± 3% (n = 14,
Additional file 2: Table S2). Hearts from patients undergo-
ing cardiac transplantation had poor contractility, left ven-
tricular ejection fraction values of 20 ± 2%, and subjected to
cardiac transplantation (n = 13, Additional file 3: Table S3).
Patients with prevalence of aortic stenosis (Additional file
2: Table S2), presented heart disease with left ventricular re-
modeling, including mild to moderate left ventricular con-
centric hypertrophy, non-hypertrophic right ventricles, and
non-left ventricular dysfunction (Stage B of heart failure).
Conversely, patients with cardiomyopathies (Additional file
3: Table S3) presented ventricular dilation and severely
symptomatic heart failure (Stage D of heart failure). Heartswere classified according to established criteria [19]. Im-
portantly, there was no significant difference in age be-
tween the two groups. The overall population with aortic
stenosis presented at an average age of 61 ± 4 years, with
overrepresentation of males (86%), whereas patients with
dilated cardiomyopathies presented at an average age of
51 ± 4 years, and were also overrepresented by males
(69%).
Analysis of gene expression in human heart biopsies
We examined whether the mRNA and protein expres-
sion of carbonic anhydrase genes are altered by cardiac
hypertrophy. We analyzed samples derived from single
endomyocardial biopsies (EMB), and ventricular slices,
respectively, from 27 human samples. An average of
1 mg of total RNA, isolated from each EMB, was sub-
jected to reverse transcription and quantification of tran-
script abundance by real-time PCR. To verify the
specificity of the real-time RT-PCR data, we performed
RT-PCR using the designed pair primers (Additional file
1: Table S1) and resolved the products on 1% agarose-
ethidium bromide gels. A single band was found for
CAII, CAIV, CAXIV, Atrial Natriuretic Peptide (ANP),
and Brain Natriuretic Peptide (BNP) transcripts, using
either brain cortex, or human heart ventricle RNA
(Figure 1A). A weak band was detected for BNP in brain
cortex, suggesting low expression in this tissue. The
presence of a single band in each case indicates the spe-
cificity of amplification, so that quantitative real-time
PCR data reports levels of a single species.
Real time reverse transcription PCR quantified the
abundance of transcripts in the heart samples. Cycle
threshold (Ct) values in real time-PCR were used as a
measure of transcript abundance, where higher thresh-
old values correspond to lower mRNA abundance and
each change of 1 cycle threshold corresponds to a two-
fold difference in message abundance. To correct for dif-
ferences in total RNA abundance between samples, each
sample was analyzed for ANP, BNP and the CA genes,
and for GAPDH (Figure 1B). To correct for variations in
the amount of mRNA assayed, cycle threshold values
were corrected by the Ct for GAPDH, assumed to be
present at a constant baseline level.
ANP and BNP are fetal genes whose expression is
induced during hypertrophic cardiomyocyte growth, or
during heart failure [20,21]. We found marked increases
of ANP and BNP expression in all hypertrophic or
dilated ventricles (failing heart), compared to non-
hypertrophic non-dilated ventricles (non-failing hearts),
or compared to ventricles with mild/moderate hyper-
trophy or dilation (non-failing hearts) (Figure 1B). Re-
markably, CAII and CAIV message increased at least
two-fold in hypertrophic ventricles, and 16-fold in failing
hearts (4 Ct difference), compared to non-hypertrophic,
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Figure 1 Carbonic anhydrase mRNA in human hearts. mRNA, isolated from adult human heart ventricles, or human brain cortex was reverse
transcribed, and the resulting cDNA was used as template for PCR (Additional file 1: Table S1). A, RT-PCR analysis of the expression levels of mRNA
encoding carbonic anhydrase II, IV, and XIV, and encoding hypertrophic markers ANP, and BNP, in adult human ventricle, and adult human brain
cortex. PCR products were analyzed on 1% agarose-ethidium bromide gels. B, mRNA expression was quantified from ventricles of non-hypertrophic
human ventricles (black bars), hypertrophic human ventricles (grey bars), or failing human ventricles (white bars), using real-time quantitative RT-PCR.
Data were corrected for individual variation with GAPDH standard curves, expressed as cycle threshold. *P < 0.05 compared to non-hypertrophic
ventricle, Paired T-test; †P < 0.05 compared to mild/moderate hypertrophic or dilated ventricle, one-way ANOVA followed by Newman-Keuls Multiple
Comparison Test. C, cycle threshold values of different genes corrected for individual variation with GAPDH, of right and left failing ventricles.
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mRNA expression did not increase in hypertrophic ventri-
cles of non-failing heart and failing ventricles. We con-
clude that hypertrophic ventricles express elevated levels
of CAII, CAIV, ANP, and BNP, message, relative to non-
hypertrophic non-dilated ventricles, which increased in
failing ventricles, as evaluated by qRT-PCR. Expression of
ANP, BNP, CAII, CAIV, and CAXIV did not differ be-
tween right and left failing ventricles (Figure 1C).
Expression of carbonic anhydrase proteins
To quantify the level of CA protein expression in hearts,
immunoblots were performed. Because of the small sizeof material collected in EMBs, it was not possible to
evaluate protein expression in samples from patients
with good prognosis (Additional file 2: Table S2). Ven-
tricular samples collected from explanted failing
explanted hearts (right or left ventricles), but with no
signs of either hypertrophy or dilation, were compared
to hypertrophic or dilated failing ventricles (Additional
file 3: Table S3).
CAII, a near-ubiquitous cytosolic isoform, is expressed
in mouse embryonic and fetal heart, and adult mouse
heart [13,22]. We examined the expression of CAII in
mouse and human hearts, by immunoblotting. Immu-
noreactivity was observed in HEK293 transiently
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HEK293 cells transfected with empty vector, (Figure 2A).
Human heart ventricular samples from explanted hearts,
and cardiomyocytes freshly isolated from adult mouse
heart, showed robust and moderate CAII expression,
respectively (Figure 2A). No immunoreactivity was
found on parallel blots incubated with non-immune
rabbit serum (not shown). The presence of endogenous
CAII in HEK293 cells has been reported previously,
using the same antibody [10].
To examine the role of CAIV and CAXIV in the failing
heart, we studied their expression (Figure 2B,C). Immu-
noreactive bands, corresponding to the expression of
CAIV and CAXIV, were observed in HEK293 cells transi-
ently transfected with rabbit CAIV, or mouse CAXIV
(Figure 3A), cDNAs. HEK293 cells transfected with empty
vector did not reveal CAIV or CAXIV immunoreactiveA
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CAIV
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Figure 2 Expression of carbonic anhydrases in hearts. A, Lysates
were prepared from adult human ventricular sample isolated from
explanted heart (see Table two) (50 μg protein), or freshly isolated
adult mouse ventricular myocytes (50 μg protein), or HEK293 cells
transfected with empty vector (30 μg protein), or HEK293 cells
transfected with human CAII (A), human CAIV B), or human CAXIV
(C) cDNA (30 μg protein), cDNA. Samples were resolved by SDS-
PAGE, transferred to PVDF membrane, and probed with anti-CAII,
CAIV or CAXIV as indicated. Filled arrows indicate position of protein.bands, indicating specificity of the antibodies. Human fail-
ing ventricles and isolated adult mouse cardiomyocytes,
showed modest and significant CAIV and CAXIV expres-
sion, respectively (Figure 2B,C). Specificity of the CAIV
antibody is indicated by the lack of band in untransfected
HEK293 cells (Figure 2B) and the specificity of the anti-
body has been previously assessed [23]. Similarly, in
untransfected HEK293 cells there is a faint band at the
CAXIV position, possibly arising from spillover from the
much stronger signal in CAXIV-transfected cells
(Figure 2C) and the antibody’s specificity has previously
been assessed [18].
Some patients with end-stage heart failure presented
with either left or right ventricles with no signs of hyper-
trophy or dilation (Additional file 3: Table S3). To evalu-
ate whether the CA isoform expression was altered in
failing ventricles with hypertrophic or dilated versus
non-hypertrophic non-dilated ventricles, protein expres-
sion was quantified by densitometry of the immunoblots
(Figure 3). CAII, CAIV, and ANP proteins could be
clearly identified on immunoblots (Figure 3). CAII,
CAIV, and ANP protein expression increased ~2 and
~2.5-fold in hypertrophic/dilated ventricles (Figure 3).
CAXIV showed a slight increase, ~35%, in dilated failing
ventricles compared to non-hypertrophic non-dilated
failing ventricles, but did not reach statistical signifi-
cance difference.
In the failing hearts, CAII, CAIV, and ANP protein ex-
pression increased in ventricles without signs of hyper-
trophy or dilation compared to hypertrophic or dilated
ventricles, demonstrating that these genes increased
under hypertrophic conditions independent of the con-
tractile performance of the heart. Conversely, failing
explanted heart, showed no differences in CAII, CAIV,
CAXIV, and ANP protein expression, in non-hypertrophic
non-dilated right ventricles, compared to non-hypertrophic
non-dilated left ventricles (Figure 3A right panel and
3B, n = 3).
Discussion
This study examined whether altered carbonic anhydrase
expression plays a role in human heart failure. Heart
failure ranges in severity from moderate impairment in
cardiac function, to significant damage that leaves the
heart unable to manage its workload [24]. This study
demonstrates that CAII and CAIV expression increased
in failing human ventricles. These enzymes need to be
considered for their contribution to the progression of
heart failure and as prognostic markers. A caveat to this
work is that the extremely small amount of material in
biopsies prevented assessment of changes of carbonic
anhydrase catalytic activity.
Similar to our findings, elevated CAII expression was
observed in rats with spontaneous hypertension and
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Figure 3 (See legend on next page.)
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Figure 3 Expression of CAII, CAIV, and ANP proteins in adult human ventricle. A, Lysates were prepared from hypertrophic/dilated (H/D), or
non-hypertrophic/non-dilated (NH/ND) adult human ventricles, from explanted failing hearts. Left panels, failing ventricles with no signs of either
hypertrophy or dilation were compared with hypertrophic or dilated failing ventricles. Protein samples (30 μg) were resolved by SDS-PAGE,
transferred to PVDF membrane, and probed with anti-CAII, anti-CAIV, anti-ANP, and anti-α-actinin antibodies. Right panels, samples from left (L)
and right (R) ventricles were directly compared. Filled arrow indicates position of protein. B, Summary of the protein expression normalized to α-
actinin. Values are expressed relative to the non-hypertrophic/non-dilated protein expression; (n = 5). C, Summary of the protein expression
normalized to α-actinin. Values are expressed relative to the control right ventricle protein expression; (n = 5). *Indicates statistically significant
difference (P < 0.05).
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angiotensin II-induced cardiac hypertrophy (TG1306/1R,
TG), and dilated cardiomyopathy with aging [26], had
increased expression of CAII, CAIV, and CAXIV, mRNA,
in addition to elevated mRNA for low-activity secreted
CAVI [27], suggesting that induction of carbonic anhy-
drases is a feature of cardiac hypertrophy. Others observed
no difference in ANP mRNA abundance between left or
right ventricle from control WKY rats, but levels increased
in either left or right hypertrophic ventricles of naturally
occurring biventricular hypertrophic rats [28].
In the human heart, the right ventricle has important
anatomical and functional differences from the left ven-
tricle. The right ventricle is a thin-walled, low-pressure
structure that unlike the left ventricle receives most of its
blood supply during systole. It has a complex, crescent
shape in contrast to the left ventricle with a simple ellips-
oid form. Differences between the two ventricles are, how-
ever, mostly related to their functions. As the left ventricle
must pump blood much further and with more resistance
than the right does, the muscular wall of the left ventricle
is far thicker to produce the necessary force. Differences
in the message and protein for CAs, ANP, and BNP genes
expressed in healthy left ventricles compared to healthy
right ventricles have not been evaluated here. We were
unable to complete this analysis since we could not obtain
comparable non-diseased ventricular material.
Carbonic anhydrases work with the AE3 Cl-/HCO3
- ex-
changer and NHE1 Na+/H+ exchanger to promote cardi-
omyocyte hypertrophy, as is found in heart failure
(Figure 4). Both AE3 and NHE1 bind to the cytosolic en-
zyme, CAII, to form a transport metabolon, the complex
of a membrane transport protein and the metabolic en-
zyme responsible for metabolism of the transported sub-
strate [10,11,29]. CAII catalytic activity (CO2 + H2O↔
HCO3
- + H+) produces HCO3
- and H+ for efflux by AE3,
and NHE1, respectively (Figure 4). Combined action of
AE3 and NHE1 results in net cellular NaCl loading,
without change of pHi, which is consistent with the
finding of elevated Na+ and unchanged pHi in pro-
hypertrophically-stimulated cardiomyocytes [30,31]. Co-
activation of NHE1-CAII and AE3 is pathological as it is
self-sustaining and NHE1 is not subject to inhibition by
alkaline pHi, since the co-activated transporters do notchange pHi [4]. We previously found that the activity of
AE3fl and NHE1 promote hypertrophy and the
hypertrophy-programmed increases expression of the
CA enzymes in cultured rat cardiomyocytes [13]. Sus-
tained NHE1/AE3 activation is itself pro-hypertrophic as
elevated Na+ decreases the efficacy of the Na+/Ca2+ ex-
changer, which normally contributes to maintenance of
low cytosolic Ca2+ levels. In turn, sustained elevated Ca2+
is a consummate hypertrophic signal, working through
the calcineurin/NFAT signaling cascade.
Recent studies also point to a pro-hypertrophic role of
CAII in rodent hearts [34]. Cardiomyocytes Car2 mice
[35], which have a disrupted caii locus, have decreased
cardiomyocyte hypertrophy in response to phenyleph-
rine. Moreover, in rat cardiomyocytes over-expression of
a catalytically-null CAII mutant inhibited cardiomyocyte
hypertrophy, in a dominant negative manner.
Here we found that CAII and CAIV mRNA levels rise
dramatically in hypertrophied and failing human hearts.
CAIV has also been found to associate with anion exchan-
gers and to enhance their transport activity, by metabol-
ism of substrate bicarbonate [23]. AE3’s HCO3
- efflux
activity is maximized by CAIV, as conversion of HCO3
- (by
CAIV) maximizes the transmembrane [HCO3
-] gradient,
which enhances the rate of HCO3
- transport. We propose
that AE3, and NHE1, CAII, and CAIV work together to
promote cardiac hypertrophy (Figure 4). Sustained co-
activation of AE3 and NHE1 is pro-hypertrophic, and this
is exacerbated by CAII and CAIV, which promote their
combined function. The increased expression of CAII and
CAIV expression in hypertrophied human myocardium is
consistent with a pathological feed-forward cascade in
which increased CAII/CAIV expression contributes to
hypertrophic signaling, including increased CA expression
(Figure 4). To intervene in the hypertrophic cascade
present in heart failure we propose that CAII and CAIV
represent targets for anti-hypertrophic therapy. Previously,
we found that the membrane permeant CA inhibitor,
6-ethoxyzolamide (ETZ, Cardrase), which targets the
HTM, intervenes in the feed-forward cascade, prevent-
ing and reversing the agonist-induced cardiomyocyte
growth [13].
As a counter-point to this argument, however, the role
of carbonic anhydrases in moderating the global activity
CAII
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HCO3-
Na+
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CalcineurinNFAT
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Figure 4 Integrative model presenting possible pro-hypertrophic action of carbonic anhydrases in cardiomyocytes. (1) Pro-hypertrophic
agonists, including phenylephrine (Phe), Angiotensin II (AngII) and endothelin I (ET) all act upon G-protein coupled receptors (GPCR). (2) In turn
protein kinase C (PKC) is activated. (3) PKC directly stimulates AE3 and indirectly stimulates NHE1, via mitogen-activated protein kinase (MAPK). (4)
Cl-/HCO3
- exchange and Na+/H+ exchange by AE3 and NHE1, respectively, are stimulated by the catalytic activity of CAII, CAIV and CAXIV. CAII
provides substrate HCO3
- and H+ for efflux respectively by AE3 and NHE1. CAXIV (anchored to the extracellular surface via a transmembrane
segment) and CAIV (anchored to the extracellular surface via a glycosylphosphatidyl inositol linkage) consume effluxed HCO3
- to maximize the
size of the transmembrane HCO3
- gradient, activating AE3. Combined activation of AE3 and NHE1 accumulates Na+ cytosolically, without effect on
pH [4,9,32,33]. (5) This rise in cytosolic Na+ compromises or reverses the ability the Na+/Ca2+ exchanger (NCX), which normally effluxes Ca2+,
driven by the transmembrane Na+ gradient. (6) Intracellular Ca++ thus rises, which activates calcineurin. (7) A major target of calcineurin is the
transcription factor, NFAT, which regulates transcription of a set of genes. Here we found that expression of CAIV and CAII in diseased human
hearts increased as heart failure progressed (double-headed red arrows).
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gested to be modest [36,37]. An alternate explanation
for the effects of CAII/CAIV on cardiac hypertrophy
could arise through more direct effects on Ca++ chan-
nels. Alterations of cytosolic pH have profound effects
on Ca++ channels [38]. Recent findings show that bicar-
bonate transporters can induce localized changed of
cytosolic pH [39], which could be especially significantin confined microenvironments of cardiomyocytes, for
example T-tubules. Localized changes of pH, arising
from carbonic anhydrase catalysis, could therefore influ-
ence Ca++ channel activity, with downstream impact on
Ca++-dependent hypertrophic signaling cascade.
The membrane permeant CA inhibitor, acetazolamide
(ACTZ, Diamox), blocks the reabsorption of sodium and
potassium by inhibiting CA in the renal tubule [40], and
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heart failure, before the advent of current loop diuretics
like furosemide [41]. Clinically, the status of congestive
heart failure in all patients receiving Diamox, clearly
improved [42]. Patients with mild heart failure were ad-
equately controlled with Diamox, whereas patients with
severe heart failure require other diuretics alone, or in
combination with Diamox [42]. More recently, ACTZ
was safely used in pediatric patients with heart disease,
to lower serum bicarbonate and acid–base excess, and
raise chloride [43]. High-dose diuretic therapy is the pri-
mary cause of metabolic alkalosis in pediatric patients
with heart disease, and carbonic anhydrase inhibition
improved this condition.
Clinical relevance of the present study includes: 1)
Carbonic anhydrase expression levels, in particular CAII
and CAIV, increase during progression of cardiac hyper-
trophy. The prognostic value of biomarkers as clinical
predictor factors in heart failure is well-established
[44-47] and this work suggests that CAII and CAIV
are molecular correlates of hypertrophy. 2) The main-
stay of treatment of acute heart failure is diuretic therapy.
Diuretics rapidly improve symptoms associated with
volume overload, while there are no data showing morbid-
ity or mortality increased from the use of chronic diuretic
therapy. CA inhibition with existing drugs could be readily
adopted to concomitantly induce diuresis and inhibit the
CA enzymes whose activity increases as hypertrophy
escalates.
Conclusion
This study suggests that ventricular hypertrophy/failure
and the augmented expression of the CA in the ventricle
may be induced by a common mechanism. Ventricular
stretch arising from an increased ventricular load leads
to the induction of CA gene expression. In this paper we
have presented evidence of elevated CA as biomarkers
for early detection of cardiac hypertrophy and heart fail-
ure, and proposing a mechanism that could improve the
cardiac performance, by CA inhibition. The ability to
distinguish individual patients at the early stage of heart
disease, by detecting elevation of CA expression, might
help to improve their functional status and prevent fur-
ther circulatory collapse that will require cardiac
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